These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 29263192

  • 1. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Suissa S.
    Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC.
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A.
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [Abstract] [Full Text] [Related]

  • 5. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY, Tecson KM, Barbin CM, Lee AY, Lerma EV, Rosol ZP, Rangaswami J, Lepor NE, Cobble ME, McCullough PA.
    Rev Cardiovasc Med; 2018 Jun 30; 19(2):41-49. PubMed ID: 31032602
    [Abstract] [Full Text] [Related]

  • 6. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 30; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK, Bandyopadhyay D, Hajra A, Biswas M, Gupta A.
    Int J Cardiol; 2016 Jun 01; 212():29-36. PubMed ID: 27017118
    [Abstract] [Full Text] [Related]

  • 8. Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physicians.
    Naing S, Poliyedath A, Khandelwal S, Sigala T.
    Postgrad Med; 2016 Nov 01; 128(8):822-827. PubMed ID: 27701934
    [Abstract] [Full Text] [Related]

  • 9. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A, Candido R, Cucinotta D, Graziano G, Rocca A, Rossi MC, Tuccinardi F, Manicardi V.
    Adv Ther; 2019 Oct 01; 36(10):2895-2909. PubMed ID: 31410779
    [Abstract] [Full Text] [Related]

  • 10. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.
    Diabetes Care; 2019 Feb 01; 42(2):318-326. PubMed ID: 30523029
    [Abstract] [Full Text] [Related]

  • 11. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
    Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, Lee S, Saarelainen L, Deruaz-Luyet A, Kyaw MH, Seino Y, EMPRISE East Asia Study Group.
    J Diabetes Investig; 2023 Mar 01; 14(3):417-428. PubMed ID: 36716212
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 13. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
    Monami M, Dicembrini I, Mannucci E.
    Acta Diabetol; 2017 Jan 11; 54(1):19-36. PubMed ID: 27488726
    [Abstract] [Full Text] [Related]

  • 14. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P.
    J Med Econ; 2019 Mar 11; 22(3):280-287. PubMed ID: 30575426
    [Abstract] [Full Text] [Related]

  • 15. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N, Mikhailidis DP, Theodorakis MJ.
    Curr Pharm Des; 2017 Mar 11; 23(10):1522-1532. PubMed ID: 28088910
    [Abstract] [Full Text] [Related]

  • 16. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH, Yoon JH, Hahn S, Cho YM.
    Diabetes Metab Res Rev; 2017 Jan 11; 33(1):. PubMed ID: 27155214
    [Abstract] [Full Text] [Related]

  • 17. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B.
    Lancet Diabetes Endocrinol; 2016 May 11; 4(5):411-9. PubMed ID: 27009625
    [Abstract] [Full Text] [Related]

  • 18. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
    Suissa S.
    Circulation; 2018 Apr 03; 137(14):1432-1434. PubMed ID: 29610125
    [No Abstract] [Full Text] [Related]

  • 19. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S.
    Crit Pathw Cardiol; 2017 Sep 03; 16(3):93-95. PubMed ID: 28742644
    [Abstract] [Full Text] [Related]

  • 20. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, Defronzo RA.
    Expert Opin Pharmacother; 2015 Sep 03; 16(18):2819-33. PubMed ID: 26583910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.